The Best Toner Pads Your Skin Will Thank You For
Korean skincare continues to trend in all forms, the latest being toner pads. Toner isn't a new skincare step, but toner pads are a trending skincare staple. These pads are conveniently packaged and pre-soaked for single use. Plus, they can be used on multiple areas on your face to target a number of skin concerns.
Toner pads are slightly different from toner. Toner pads provide a physical way to effectively exfoliate your face. It combines the power of a toner with a cleansing pad to remove dirt, impurities and makeup from your face. In addition, toner pads are offered in a number of different versions. Some brighten, reduce the appearance of wrinkles and control blemishes on the skin. Explore the different toner pad offerings to find which one is right for you.
Best For Healthy Aging: HydroPeptide Clarifying Toner Balance Control Pads
Best For Dry Skin: Peach & Lily Lazy Day All-In-One Moisture Pads
Best Exfoliating Pads: First Aid Beauty Facial Radiance Pads
Best For Sensitive Skin: Elemis Dynamic Gentle Resurfacing Pads
Best For Acne-Prone Skin: Mediheal Madecassoside Blemish Pad
HydroPeptide Clarifying Toner Balance Control Pads
$49
Buy Now
Photo Courtesy of Nordstrom
The HydroPeptide Clarifying Toner Balance Control Pads are a staple skincare product for graceful aging. Containing ingredients like alpha hydroxy acids and a pore-cleansing peptide, these pads prevent signs of visible aging. They clean your skin and improve its texture making it smoother and healthy looking.
Peach & Lily Lazy Day All-In-One Moisture Pads
$43
Buy Now
Photo Courtesy of Ulta
For those who shy away from toners because they're too harsh, opt for the Peach & Lily Lazy Day All-In-One Moisture Pads. Featuring moisture in the name, these toner pads moisturize, tone and hydrate your skin. It contains hyaluronic acid which quite literally saturates your skin with hydration. Plus, it includes bamboo to restore your skin's natural barrier.
First Aid Beauty Facial Radiance Pads
$38
Buy Now
Photo Courtesy of Sephora
The First Aid Beauty Facial Radiance Pads are a 2-in-1 product. They feature Glycolic and Lactic Acids to exfoliate the skin and lemon peel to brighten the skin. These pads are gentle on your skin yet effective, helping get rid of the dead skin on your face.
Elemis Dynamic Gentle Resurfacing Pads
$65
Buy Now
Photo Courtesy of Sephora
The Elemis Dynamic Gentle Resurfacing Pads are like aesthetician grade products in a container. According to a clinical trial conducted for 36 people over the course of 4 weeks, 100 percent claimed 'these were the best resurfacing facial pads they ever used.' These pads speed up your skin's natural cell turnover process and reduce wrinkles. Plus, it's safe enough for all skin types, including those with sensitive skin.
Mediheal Madecassoside Blemish Pad
$24
Buy Now
Photo Courtesy of Ulta
The Mediheal Madecassoside Blemish Pad is the toner pad for post-pimple-prone skin. Simply apply the wide, rounded patches to your skin as a sheet mask. Then, swipe it across your face to effectively treat your post-blemish scarred skin. Ingredients include centella asiatica, which soothes your irritated skin after a nasty breakout.
Our editors love finding you the best products and offers! If you purchase something by clicking on one of the affiliate links on our website, we may earn a commission at no extra cost to you.The post The Best Toner Pads Your Skin Will Thank You For appeared first on 21Ninety.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
13 hours ago
- Los Angeles Times
Millions of Californians who rely on Medi-Cal and In-Home Supportive Services could lose eligibility
VIDEO | 01:28 Millions of Californians who rely on Medi-Cal and In-Home Supportive Services could lose eligibility
New York Post
16 hours ago
- New York Post
The medicube Age-R Booster Pro is the Beyoncé of beauty tools
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Let's talk skincare gadgets. Because let's face it: we've all been seduced by that sleek ad, the influencer with glass skin, or the promise that this one little device will reverse the effects of binge-watching Netflix under fluorescent lights while eating cheese puffs. Enter the Age-R Booster Pro — a name that sounds like a spaceship but is specially designed to make your face look like it drinks collagen for breakfast. As someone who reports on and reviews the best beauty brands for a living, I'm here to tell you that medicube is certainly worth it. Now, its device is beating the same buzzy drum and is on sale for less than $200 for a limited time. Amazon This snazzy Korean-made device is marketed as a product to help you 'achieve your glass skin goals with innovative technology' tool. Translation: it uses tiny zaps and heat to wake up your collagen, tighten any sagging skin and lift those brows like a pop diva hitting a high note. According to medicube, it's the closest you can get to a med spa treatment without leaving your house (and, that's always a plus). If you're in the mood for a skincare investment, this device feels like unwrapping tech from the future. It's white, sleek, and vaguely resembles something that might take your temperature — or steal your Wi-Fi. As far as aesthetics go, it checks every box. Just don't expect it to fit neatly in your carry-on unless you travel with a dedicated 'skincare gadgets only' suitcase (no judgment if you do). How it works No goopy gel? Count me in. The medicube Age-R Booster Pro combines electroporation, microcurrent, EMS, electric needles, LED light therapy and sonic vibration into a single device. It's like having a facialist, dermatologist and spa therapist all rolled into one — without the hefty price tag or awkward small talk. Each of the four modes is designed to target specific skin concerns with precision. The Air Shot mode uses electric needles to refine pores and combat acne, while the Booster mode employs electroporation to enhance product absorption and brighten your complexion. Its Microcurrent mode stimulates collagen production for a lifted, youthful appearance, and the Derma Shot mode utilizes EMS to tone and firm facial muscles. Not to mention, tthe device features five LED light settings — blue, orange, green, red and purple — each tailored to address different skin issues, from acne to dullness to elasticity. The device boasts a skin-contact sensor that activates LED light only when it touches your skin, ensuring safe and effective treatment. It also includes a built-in timer and voice guide to keep you on track during your skincare session. For those seeking a more personalized experience, the AGE-R app offers customized treatment plans, progress tracking and expert tips. Most reviewers say it's like a cozy face sauna. The Ultra Tune comes with five interchangeable heads, each designed to contour around your face like a skincare GPS. Bonus: It makes you feel like a highly-trained beauty assassin on a mission to slay wrinkles. It's easy to use, and you don't need a special gel. Simply use the Ultra Tune after your skincare products have fully absorbed. It will help boost your skin's radiance and elasticity when used consistently, which is the best part. Pro tip: use the brand's Deep Vita C Capsule Cream that's also on sale for a brightening boost. People are seeing real results, too. Reviewers have posted everything from 'my cheeks look lifted' to 'I finally have cheekbones and didn't have to contour.' And yes, we're talking after just a few uses. But others say it's more of a 'slow and steady wins the race' situation. TL;DR: This isn't a Disney princess transformation; consistency is key. Let's not tiptoe around it — this baby, though on sale, is nearly $200 . That's not exactly pocket change. But, compared to repeated spa visits, it's a steal. The real question is: will you actually use it three times a week, or will it become the world's fanciest dust collector? That's up to you to decide. The bottom line If you're skincare-obsessed, love a tech-forward approach, or just want to pretend you're giving yourself a facial while watching 'Bridgerton,' this device is for you. If your ideal skincare routine is 'splash water and hope for the best,' maybe skip it. Honestly? The medicube Age-R Booster Pro brings the science and the sizzle. It's not perfect, it's not cheap, but it works if you commit to using it consistently. It's only worth it if you consider this device like a skincare marriage of sorts, not a fling. If you're tired of overpriced creams that promise the world and deliver very little, this device is a solid investment. It's bougie. It's bold. It's your new skincare BFF with benefits. Just remember: good skin takes time, tec,h and maybe a little caffeine. This article was written by Victoria Giardina, New York Post Commerce Journalist & Content Strategist, who has spent countless hours researching, testing hundreds of products and comparing the latest makeup, skincare, hair and beauty items and trends to determine what's truly worth your hard-earned cash. She evaluates formulas, textures, ingredients and more, in addition to consulting medical and industry experts. Some of Victoria's latest conquests include testing the best vitamin C serums on the market, and a rinse-and-repeat review of the best shampoos of 2025. Victoria, who received a beauty industry essentials certification from the Fashion Institute of Technology, has been creating shopping guides for the New York Post since 2021 and previously held positions at Insider Reviews and CNN Underscored. Looking for a headline-worthy haul? Keep shopping Post Wanted.
Yahoo
a day ago
- Yahoo
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $11 million Sales milestones of $150 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ('Ocugen' or the 'Company') (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP). Pursuant to the term sheet, under the license agreement Ocugen will receive upfront license fees and near-term development milestones equaling up to $11 million. The Company will be entitled to sales milestones of $1 million for every $15 million of net sales in Korea in addition to a royalty of 25% on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement. There are an estimated 15,000 individuals in the Republic of Korea with RP. OCU400 provides the opportunity for our partner to help thousands of patients and become a leader in gene therapy in Korea. 'This regional licensing agreement is aligned with our business development strategy to partner with well-established companies in their respective countries and regions—leveraging their networks and know-how to treat as many RP patients as possible,' said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. 'A regional approach preserves Ocugen's rights to larger geographies to maximize total patient reach while also generating return for our shareholders.' Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 60 days. Ocugen is currently advancing OCU400 through Phase 3 clinical development with a target Biologics License Application filing of mid-2026. About Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at and follow us on X and LinkedIn. Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the terms of the definitive license and timing of a definitive agreement or if a definitive agreement will be executed at all or the anticipated benefits to Ocugen of the definitive license agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that a definitive agreement for the license will be delayed or not executed at all, or that, if executed, it will not be on terms described above, the risk that contemplated license agreement, if executed, will not lead to the current anticipated benefits to Ocugen, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; the ability of OCU400 to perform in humans in a manner consistent with nonclinical or preclinical study data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled 'Risk Factors' in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release. Contact:Tiffany HamiltonAVP, Head of Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
